Mumbai, July 26
Lupin Ltd has received regulatory approval to conduct the second phase of human-trials on its prospective drug targeting psoriasis, a skin-related condition.
The Drug Controller General of India (DCGI) has given its approval to conduct Phase-II clinical trials for its psoriasis pure compound LL-4218 (Desoside-P), a note from Lupin said.
In Phase II trials, the prospective medicine is targeted at a sample-size of 100-500 human subjects infected with the disease. Lupin expects to begin clinical trials at about six centres immediately, a note from the company said. The total market for psoriasis is estimated to be in excess of $2 billion. The company also has three other new chemical entities in various stages of clinical trials, the note added.